Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Strata Critical Medical, Inc., formerly Blade Air Mobility, Inc., files regulatory documents that document the company's transition from a broader air mobility platform to a critical medical business. The filings cover the completed Passenger business disposition, the corporate name change, Nasdaq-listed common stock under SRTA, and warrant-related capital-structure actions, including a Form 25 for removal of warrants from listing and registration.
Its 8-K reports and proxy materials disclose operating results from continuing operations, logistics and clinical revenue categories, material agreements, acquisition activity, credit arrangements involving operating subsidiaries such as Trinity Air Medical and Keystone Perfusion Services, and annual meeting governance matters. The record also includes exhibit filings, Inline XBRL cover data, and stockholder voting disclosures tied to the rebranded issuer.
CFO William A. Heyburn reported three transactions in Blade Air Mobility (BLDE) stock. On 08/01/2025 he received 139,286 Class A shares after the Compensation Committee certified that 2024 performance targets tied to previously granted PSUs had been achieved. To satisfy related tax obligations, the company withheld 76,177 shares at $3.99.
Following the vesting, Heyburn beneficially owned 1,463,940 shares. On 08/04/2025, acting under a pre-arranged Rule 10b5-1 plan dated 11/25/2024, he sold 46,918 shares at a weighted-average price of $4.94-$4.96, trimming his stake to 1,340,845 shares. The sale represents roughly 3 % of his current holdings and generated about $232k in gross proceeds. Net of all reported moves, Heyburn’s ownership increased by approximately 16 k shares, or +1 %.
No options or other derivative securities were transacted, and no additional insider participants were listed. Overall, the filing reflects routine equity compensation vesting combined with a modest, pre-scheduled liquidity sale, leaving the CFO with a substantial position aligned with shareholders.
Blade Air Mobility (NASDAQ: BLDE) Q2 2025 10-Q highlights
- Revenue rose 4% YoY to $70.8 m; Medical segment up 18% to $45.1 m, offsetting a 13% Passenger decline to $25.7 m.
- Cost discipline: Total operating expenses fell 5% to $75.8 m, driven by a 20% reduction in G&A and 32% lower selling & marketing spend.
- Profitability improving: Operating loss narrowed to $(5.0) m from $(12.1) m; net loss trimmed to $(3.7) m (-$0.05/sh) versus $(11.3) m (-$0.15/sh) prior-year.
- Segment Adjusted EBITDA grew 34% to $8.4 m; Medical contributed $6.0 m.
- Liquidity: Cash & equivalents $58.8 m plus $54.7 m short-term Treasuries; operating cash burn cut to $3.3 m (vs $7.1 m).
- Balance sheet: Warrant liability marked down to $3.0 m (from $5.8 m); goodwill now $44.3 m after organ-transport acquisitions.
- Share count: 81.7 m shares outstanding, up 2.3 m YTD due to equity compensation; stock-based comp $9.6 m YTD.
- Subsequent event: 1 Aug 25 agreement to sell Passenger business to Joby Aviation for up to $125 m ($90 m at close, $35 m earn-out, cash or JOBY stock). Transaction expected to be treated as discontinued operations.
- Guidance: none provided; management notes seasonality with stronger Q2–Q3 passenger demand.
Key takeaways: Blade is pivoting toward its higher-margin Medical segment while monetizing the Passenger operation. Liquidity remains solid and losses are shrinking, but execution risk on the Joby deal and continued passenger softness warrant monitoring.